reports
Inventiva announces filing of its 2024 Universal Registration Document...
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December ...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel ...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son Rapport Annuel 2024 (« Form 20-F ») Daix (France), New York City (New York, États-Unis), le 15 avril 2025 - Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH ») et d'autres maladies avec un besoin médical non satisfait, annonce aujourd’hui avoir déposé son Document d’Enreg...
- Robert Jan Vos
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
Sequana Medical CMS proposes NTAP top up payment for the alfapump
Sequana announced that the Centers for Medicare and Medicaid Services (CMS) recommends that alfapump system cases be eligible for incremental payment via a new technology add-on payment (NTAP). This proposal could bring an NTAP top-up payment of up to $ 19,500 on top of the existing DRG payments, boosting the device's reimbursement position, and could make the alfapump procedure profitable for hospitals, which is likely to help drive adoption. With center training due to be completed by the end ...
- ING Helpdesk
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Couvreur
- Wim Hoste
- Jacob Mekhael
Inventiva FIRST LOOK: Completes NATiV3 enrolment, topline results pinn...
Inventiva announced the completion of patient enrolment in its phase 3 (NATiV3) trial of lanifibranor (pan-PPAR agonist) in MASH. This is a key milestone, particularly in the context of the difficulties associated with MASH trial recruitment. As a result, the timeline for the topline readout is now pinned to 2H26 taking into account the 72 weeks treatment period. Subject to the second tranche of ~€ 116m from the financing announced in October 2024, which is expected to be triggered in 2Q25, Inve...
Inventiva announces completion of enrollment in the Phase 3 NATiV3 cli...
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory approval Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compan...
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3...
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée Objectifs de recrutement dépassés avec 1.009 patients randomisés dans la cohorte principale et 411 dans la cohorte exploratoirePrincipaux résultats de NATiV3 attendus au deuxième semestre 2026 et, si positifs, ils supporteront les demandes règlementaires d’autorisation de mise sur le marché Daix (France), New York City (New York, États-Unis), le 1 avril 2025 - Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Sociét...
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Sharad Kumar S.P
- Thomas Couvreur
- Wim Hoste
- Jacob Mekhael
Inventiva FIRST LOOK: FY24 results confirm NATiV3 enrolment completion...
Inventiva reported FY24 results with a cash position of € 96.6m (YE23: €36m), providing a runway until mid 3Q25. The update comes in line with our expectations, and the progress made in recruitment for the phase 3 (NATiV3) trial of lanifibranor in MASH means the company continues to expect completion of enrolment in 1H25. This would secure the timeline for the topline readout, expected in 2H26. With the additional funding from the second tranche of the financing announced in October 2024 expecte...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Inventiva reports its 2024 full year results and provides a business u...
Inventiva reports its 2024 full year results and provides a business update Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce...
Inventiva publie ses résultats financiers annuels 2024 et fait le poin...
Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024Levée d’un produit brut de 116 millions d’euros dans le cadre de la première tranche du Financement Structuré pouvant atteindre un montant total de 348 millions d'euros Dernier patient screené dans l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor dans la MASH début janvier 2025 Projet de réorganisation stratégique des activités présenté au comité social e...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
Inventiva announces the schedule of publication and presentation of it...
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2024 full-year fin...
Inventiva annonce la date de publication et de présentation de ses rés...
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2024 Daix (France), New York City (New York, Etats-Unis), le 19 mars 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH ») et d’autres maladies avec un besoin médical non satisfait, annonce aujourd’hui que son équipe de direction présentera les résultats financiers...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.